Waldenstrom's Macroglobulinemia Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Whole genome sequencing opens door for targeted Waldenstrms therapy
Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the current outlook of Waldenstrms macroglobulinemia (WM), from hand-me-down to targeted approaches. The discovery ... Author: VJHemOnc Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Exciting new therapy for Waldenstrms macroglobulinemia: ibrutinib plus rituximab
Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenstrms macroglobulinemia (WM) were presented at the 23rd congress of the European Hematology As... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Meletios Exciting new therapy for Waldenstrms macroglobulinemia: ibrutinib plus rituximab
Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenstrms macroglobulinemia (WM) were presented at the 23rd congress of the European Hematology As... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Positive results for acalabrutinib in Waldenstrm's macroglobulinemia
BTK inhibition is a popular avenue of treatment research in Waldenstrm's macroglobulinemia (WM). In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, in Sto... Author: VJHemOnc Added: 08/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel BTK inhibitors for Waldenstrms macroglobulinemia
Ramon Garcia-Sanz, MD, PhD from the University Hospital of Salamanca, Salamanca, Spain, shares exciting data in Waldenstrms macroglobulinemia (WM) from the 23rd congress of European Hematology Assoc... Author: VJHemOnc Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts

iNNOVATE results: a prospective new standard of care for Waldenstrms macroglobulinemia
The purpose of the iNNOVATE study (NCT02165397) was to evaluate the safety and efficacy of ibrutinib and rituximab for the treatment of Waldenstrms macroglobulinemia (WM). Here, at the 23rd congress... Author: VJHemOnc Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts

Unmet needs in Waldenstrms macroglobulinemia
Although there is a lot known about Waldenstrms macroglobulinemia (WM), there is little understanding of the wild-type and IgM-related disorders. During this interview, Steven Treon, MD, PhD, from ... Author: VJHemOnc Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel therapeutic options for Waldenstrms macroglobulinemia
The therapeutic potential for Waldenstrms macroglobulinemia (WM) is widening, with our growing understanding and knowledge of the genetics behind this disease. In this interview at the 1st European ... Author: VJHemOnc Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Waldenstrom Macroglobulinemia is Rare Disease Results of study are the most clinically relevant
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Waldenstrom Macroglobulinemia is Rare Disease Results of study are the most clinically relevant at ASCO 2018 Author: Annual-Meeting Added: 06/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2018 Category: Cancer & Oncology Source Type: podcasts

Acalabrutinib is Another BTK Inhibitor Active drug for Waldenstrom Macroglobulinemia
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Acalabrutinib is Another BTK Inhibitor Active drug for Waldenstrom Macroglobulinemia at ASCO 2018 Author: Annual-Meeting Added: 06/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2018 Category: Cancer & Oncology Source Type: podcasts

Innovate Trial - Randomized Placebo Control 150 patients with Waldenstrom Macroglobulinemia
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Innovate Trial - Randomized Placebo Control 150 patients with Waldenstrom Macroglobulinemia at ASCO 2018 Author: Annual-Meeting Added: 06/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2018 Category: Cancer & Oncology Source Type: podcasts

New insights into the biology and treatment of Waldenstrm Macroglobulinemia
In this presentation from Lymphoma & Myeloma 2016, Dr. Steven Treon discusses new insights into the biology and treatment of Waldenstrm Macroglobulinemia.<br /><br />Click to Earn CME Credit: <a target='_blank' href='http://bit.ly/2'>http://bit.ly/2...</a>... Author: imedex Added: 03/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 8, 2017 Category: Cancer & Oncology Source Type: podcasts

Indications for systemic therapy of Waldenstroms Macroglobulinemia
Morie A. Gertz, MD of Mayo Clinic discusses the indications for systemic therapy of Waldenstroms Macroglobulinemia at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Die... Author: ScrippsHealth Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts

Standard of care options for frontline therapy of Waldenstroms Macroglobulinemia
Morie A. Gertz, MD of Mayo Clinic discusses the standard of care options for frontline therapy of Waldenstroms Macroglobulinemia at Scripps Health 36th Annual Conference: Clinical Hematology and Oncol... Author: ScrippsHealth Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts

Roles of proteasome inhibitors and immunomodulatory agents in Waldenstroms Macroglobulinemia
Morie A. Gertz, MD of Mayo Clinic discusses the roles of proteasome inhibitors and immunomodulatory agents in Waldenstroms Macroglobulinemia at Scripps Health 36th Annual Conference: Clinical Hematolo... Author: ScrippsHealth Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts